TY  - JOUR
AU  - Bexte, Tobias
AU  - Reindl, Lisa Marie
AU  - Ullrich, Evelyn
TI  - Non-viral technologies can pave the way for CAR-NK cell therapy.
JO  - Journal of leukocyte biology
VL  - 114
IS  - 5
SN  - 0741-5400
CY  - Hoboken, NJ
PB  - Wiley
M1  - DKFZ-2023-01349
SP  - 475-486
PY  - 2023
N1  - 2023 Oct 26;114(5):475-486
AB  - Natural killer (NK) cells are a promising platform for cancer immunotherapy. NK cells have high intrinsic killing capability, and the insertion of a chimeric antigen receptor (CAR) can further enhance their anti-tumor potential. In first human trials, CAR-NK cells demonstrated strong clinical activity without therapy-induced side effects. The applicability of NK cells as an 'off-the-shelf' product makes them highly attractive for gene-engineered cell-therapies. Traditionally, viral transduction has been used for gene-editing; however, the use of viral vectors remains a safety concern and is associated with high costs and regulatory requirements. Here, we review the current landscape of non-viral approaches for CAR-NK cell generation, which include transfection of vector particles and electroporation of mRNA and DNA vectors resulting in transient gene-modification and CAR expression. In addition, using non-viral transposon technologies, NK cells can be stably modified ensuring long-lasting CAR expression. Finally, we discuss CRISPR/Cas9 tools to edit key genes for NK cell functionality.
KW  - CAR (Other)
KW  - CRISPR (Other)
KW  - electroporation (Other)
KW  - mRNA (Other)
KW  - natural killer cell (Other)
KW  - non-viral (Other)
KW  - transposon (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37403203
DO  - DOI:10.1093/jleuko/qiad074
UR  - https://inrepo02.dkfz.de/record/277341
ER  -